Literature DB >> 28662409

Human placental mesenchymal stem cells of fetal origins-alleviated inflammation and fibrosis by attenuating MyD88 signaling in bleomycin-induced pulmonary fibrosis mice.

Feng Li1, Fei Han2, Hui Li2, Jia Zhang2, Xia Qiao3, Juan Shi3, Li Yang4, Jianda Dong5, Meihui Luo3, Jun Wei6, Xiaoming Liu7.   

Abstract

Pulmonary fibrosis is a progressive lung disease that its pathogenic mechanism currently is incompletely understood. Toll-like receptor (TLR) signaling has recently been identified as a regulator of inflammation and pulmonary fibrosis. In addition, mesenchymal stem cells (MSCs) of different origins offer a great promise in treatment of idiopathic pulmonary fibrosis (IPF). However mechanisms of pathogenic roles of TLR signaling and therapeutic effects of MSCs in the IPF remain elusive. In present study, the involvement of TLR signaling and the therapeutic role of MSCs were interrogated in MyD88-deficient mice using human placental MSCs of fetal origins (hfPMSCs). The results showed an alleviated pulmonary inflammation and fibrosis in myeloid differentiation primary response gene 88 (MyD88)-deficient mice treated with bleomycin (BLM), accompanied with a reduced TGF-β signaling and production of pro-fibrotic cytokines, including TNF-α, IL-1β. An exposure of HLF1 lung fibroblasts, A549 epithelial cells and RAW264.7 macrophages to BLM led an increased expression of key components of MyD88 and TGF-β signaling cascades. Of interest, enforced expression and inhibition of MyD88 protein resulted in an enhanced and a reduced TGF-β signaling in above cells in the presence of BLM, respectively. However, the addition of TGF-β1 showed a marginally inhibitory effect on MyD88 signaling in these cells in the absence of BLM. Importantly, the administration of hfPMSCs could significantly attenuate BLM-induced pulmonary fibrosis in mice, along with a reduced hydroxyproline (HYP) deposition, MyD88 and TGF-β signaling activation, and production of pro-fibrotic cytokines. These results may suggest an importance of MyD88/TGF-β signaling axis in the tissue homeostasis and functional integrity of lung in response to injury, which may offer a novel target for treatment of pulmonary fibrosis.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; Inflammation; Mesenchymal stem cells; Myeloid differentiation factor 88; Pulmonary fibrosis; T cell growth factor beta

Mesh:

Substances:

Year:  2017        PMID: 28662409     DOI: 10.1016/j.molimm.2017.06.032

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  10 in total

1.  Jinlian Xiaodu Decoction Protects against Bleomycin-Induced Pulmonary Fibrosis in Rats.

Authors:  Zhiqiang Wu; Qin He; Feibao Tao; Xuxing Ye; Saibin Wang; Yijun Zhu; Liang Zhu; Bin Xu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-23       Impact factor: 2.650

2.  Anti-Inflammatory and Anti-Fibrotic Effect of Immortalized Mesenchymal-Stem-Cell-Derived Conditioned Medium on Human Lung Myofibroblasts and Epithelial Cells.

Authors:  Eirini Filidou; Leonidas Kandilogiannakis; Gesthimani Tarapatzi; Michail Spathakis; Paschalis Steiropoulos; Dimitrios Mikroulis; Konstantinos Arvanitidis; Vasilis Paspaliaris; George Kolios
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

Review 3.  Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities.

Authors:  Susan Moradinasab; Atieh Pourbagheri-Sigaroodi; Parisa Zafari; Seyed H Ghaffari; Davood Bashash
Journal:  Int Immunopharmacol       Date:  2021-04-28       Impact factor: 5.714

Review 4.  The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System.

Authors:  Georgina M Ellison-Hughes; Liam Colley; Katie A O'Brien; Kirsty A Roberts; Thomas A Agbaedeng; Mark D Ross
Journal:  Front Cardiovasc Med       Date:  2020-12-09

Review 5.  Promises and Challenges of Cell-Based Therapies to Promote Lung Regeneration in Idiopathic Pulmonary Fibrosis.

Authors:  Alejandro Egea-Zorrilla; Laura Vera; Borja Saez; Ana Pardo-Saganta
Journal:  Cells       Date:  2022-08-20       Impact factor: 7.666

Review 6.  Stem cell-based therapy for pulmonary fibrosis.

Authors:  Wenzhao Cheng; Yiming Zeng; Dachun Wang
Journal:  Stem Cell Res Ther       Date:  2022-10-04       Impact factor: 8.079

Review 7.  Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution.

Authors:  Anna Valeria Samarelli; Roberto Tonelli; Irene Heijink; Aina Martin Medina; Alessandro Marchioni; Giulia Bruzzi; Ivana Castaniere; Dario Andrisani; Filippo Gozzi; Linda Manicardi; Antonio Moretti; Stefania Cerri; Riccardo Fantini; Luca Tabbì; Chiara Nani; Ilenia Mastrolia; Daniel J Weiss; Massimo Dominici; Enrico Clini
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

Review 8.  Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis.

Authors:  Argyrios Tzouvelekis; Rebecca Toonkel; Theodoros Karampitsakos; Kantha Medapalli; Ioanna Ninou; Vasilis Aidinis; Demosthenes Bouros; Marilyn K Glassberg
Journal:  Front Med (Lausanne)       Date:  2018-05-15

Review 9.  Cell Therapy in Idiopathic Pulmonary Fibrosis.

Authors:  Anna Serrano-Mollar
Journal:  Med Sci (Basel)       Date:  2018-08-13

Review 10.  Effects of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Future Perspectives.

Authors:  Haiyan Guo; Yue Su; Fang Deng
Journal:  Stem Cell Rev Rep       Date:  2020-11-19       Impact factor: 5.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.